456 Studies Now Enrolling
Phase I study evaluating combination therapy with the receptor tyrosine kinase inhibitor PLX3397 and Sirolimus in patients with unresectable sarcoma and Phase II study in malignant peripheral nerve sheath tumors
A Study for Patients with Malignant Peripheral Nerve Sheath Tumors Using Study Drugs PLX3397 and Sirolimus
| Sponsor: | Plexxikon and FDA |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAO6059 |
| U.S. Govt. ID: | NCT02584647 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerated dose of the study drug will be determined. In the phase II portion, progression-free survival will be assessed at the dose level found in Phase I. Participants will continue to take study drug until they experience an unacceptable side effect or their disease progresses.
This study is closed
